⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

BAYERCROP - Fundamental Analysis: Financial Health & Valuation

← Back to List

⭐ Rating: 3.7

Last Updated Time : 12 Sept 26, 09:13 pm

Key Parameters

⭐ Fundamental Rating: 3.7

ROE23.7 %
ROCE29.1 %
Stock P/E24.4
Industry PE20.8
PEG Ratio46.0
Debt to equity0.03
EPS163 ₹
Book Value660 ₹
Show all parameters (20 more)
Stock CodeBAYERCROP
Market Cap17,855 Cr.
Current Price3,974 ₹
High / Low5,489 ₹
Dividend Yield3.77 %
Face Value10.0 ₹
DMA 504,118 ₹
DMA 2004,449 ₹
Chg in FII Hold0.08 %
Chg in DII Hold-0.25 %
PAT Qtr322 Cr.
PAT Prev Qtr162 Cr.
RSI37.9
MACD-50.3
Volume21,147
Avg Vol 1Wk12,821
Low price3,865 ₹
High price5,489 ₹
52w Index6.72 %
Qtr Profit Var15.4 %

🏭 Industry

The agricultural chemicals and seeds industry is characterized by capital-intensive operations, cyclical demand driven by weather patterns and commodity prices, and significant R&D investment for new products. Companies within this sector often exhibit strong brand recognition but are subject to regulatory scrutiny and potential litigation risks – a factor the recent news highlights.

✅ Positive

Bayer CropScience demonstrates strong profitability with a PAT growth of 15.4% and an impressive ROCE of 29.1%. The company maintains a conservative capital structure, indicated by a debt-to-equity ratio of just 0.03, providing financial flexibility. Consistent dividend payments at 3.77% add to the attractiveness for income-oriented investors.

⚠️ Limitation

The high P/E ratio of 24.4 relative to the industry average of 20.8 raises concerns about potential overvaluation, especially considering the PEG ratio is a very elevated 46.0. Furthermore, reliance on macroeconomic conditions surrounding agricultural commodity prices creates volatility within revenue streams and margins.

📉 Company Negative News

Recent news indicates Bayer CropScience share price fell to a fresh 52-week low alongside concerning updates regarding delayed earnings forecasts for 2026; this could impact investor sentiment and valuations negatively. Another headline indicates an ongoing legal risk relating to crop science, weighing on stock valuation.

📈 Company Positive News

The company's robust performance in Crop Science continues to support the overall outlook as reported through news headlines. FII holdings have increased by 0.08%, offering a modest increase in institutional confidence.

🧾 Long-Term Outlook

An entry zone could be established around 3,865 ₹ (low price), recognizing the current market discount. Long-term holding guidance would involve monitoring revenue growth rates, specifically focusing on Crop Science’s performance as a key driver of profitability. The investment merits consideration given the strong returns generated and manageable financial structure, but vigilance regarding macroeconomic risks and potential litigation remains crucial; overall rating: hold cautiously.

Choose Technical Analysis or Fundamental Analysis above to load it.

How BAYERCROP Rates Across All Strategies

★ 3.7
Entry Price: 3,761 ₹.
★ 2.3
Buy Price: 3,761 ₹ (just below current low).
★ 3.2
An entry zone between 3,600 ₹ and 3,800 ₹ would represent a reasonabl…
★ 2.7
Short-term entry zones would be around 3,761 ₹ (support level) and 4,…
Fundamental
★ 3.7
You're viewing this analysis below.

NIFTY 50 · Fundamental

NEXT 50 · Fundamental

MIDCAP · Fundamental

SMALLCAP · Fundamental